Share this article
Share this article
NEW YORK, July 28, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against DraftKings Inc. f/k/a Diamond Eagle Acquisition Corp. ( DEAC , DraftKings , or the Company ) (NASDAQ: DKNG) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-05739, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired DraftKings securities between December 23, 2019 and June 15, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Share this article
Share this article
NEW YORK, July 28, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ( AcelRx or the Company ) (NASDAQ: ACRX) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Share this article
Share this article
NEW YORK, July 28, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against CorMedix Inc. ( CorMedix or the Company ) (NASDAQ: CRMD) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-14020, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CorMedix securities between July 8, 2020 and May 13, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Share this article
Share this article
NEW YORK, July 28, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against CarLotz, Inc. ( CarLotz or the Company ) (NASDAQ: LOTZ; LOTZW) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-06191, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CarLotz securities between December 30, 2020 and May 25, 2021, inclusive (the Class Period ). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the Exchange Act ).
Share this article
Share this article
NEW YORK, July 28, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ( Ocugen or the Company ) (NASDAQ: OCGN) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 21-cv-03182, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Ocugen securities between February 2, 2021, and June 10, 2021, inclusive (the Class Period ), seeking to recover damages for violations of the federal securities laws under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ), and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.